Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria

Suzanne Geerlings; Vivian Fonseca; David Castro-Diaz; James List; Shamik Parikh

doi:https://doi.org/10.1016/j.diabres.2013.12.052

Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria

Suzanne Geerlings, Vivian Fonseca, David Castro-Diaz, James List, Shamik Parikh

Research output: Contribution to journal › Article › Academic › peer-review

190 Citations (Scopus)

Abstract

Predisposition to genital infections and urinary tract infections (UTIs) in type 2 diabetes mellitus (T2DM) results from several factors such as glucosuria, adherence of bacteria to the uroepithelium and immune dysfunction. The tendency to develop these infections could be even higher in patients with T2DM treated with the emerging class of sodium-glucose cotransporter-2 (SGLT2) inhibitors. Studies have shown that pharmacologically-induced glucosuria with SGLT2 inhibitors raises the risk of developing genital infections and, to a relatively lesser extent, UTIs. However, a definitive dose relationship of the incidence of these infections with the SGLT2 doses is not evident in the existing data. Therefore, the precise role of glucosuria as a causative factor for these infections is yet to be fully elucidated

Original language	English
Pages (from-to)	373-381
Journal	Diabetes Research and Clinical Practice
Volume	103
Issue number	3
DOIs	https://doi.org/10.1016/j.diabres.2013.12.052
Publication status	Published - 2014

Access to Document

https://doi.org/10.1016/j.diabres.2013.12.052

Cite this

@article{adc1daf1edbd487eadfa58e7add64a48,

title = "Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria",

abstract = "Predisposition to genital infections and urinary tract infections (UTIs) in type 2 diabetes mellitus (T2DM) results from several factors such as glucosuria, adherence of bacteria to the uroepithelium and immune dysfunction. The tendency to develop these infections could be even higher in patients with T2DM treated with the emerging class of sodium-glucose cotransporter-2 (SGLT2) inhibitors. Studies have shown that pharmacologically-induced glucosuria with SGLT2 inhibitors raises the risk of developing genital infections and, to a relatively lesser extent, UTIs. However, a definitive dose relationship of the incidence of these infections with the SGLT2 doses is not evident in the existing data. Therefore, the precise role of glucosuria as a causative factor for these infections is yet to be fully elucidated",

author = "Suzanne Geerlings and Vivian Fonseca and David Castro-Diaz and James List and Shamik Parikh",

year = "2014",

doi = "https://doi.org/10.1016/j.diabres.2013.12.052",

language = "English",

volume = "103",

pages = "373--381",

journal = "Diabetes Research and Clinical Practice",

issn = "0168-8227",

publisher = "Elsevier Ireland Ltd",

number = "3",

}

TY - JOUR

T1 - Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria

AU - Geerlings, Suzanne

AU - Fonseca, Vivian

AU - Castro-Diaz, David

AU - List, James

AU - Parikh, Shamik

PY - 2014

Y1 - 2014

N2 - Predisposition to genital infections and urinary tract infections (UTIs) in type 2 diabetes mellitus (T2DM) results from several factors such as glucosuria, adherence of bacteria to the uroepithelium and immune dysfunction. The tendency to develop these infections could be even higher in patients with T2DM treated with the emerging class of sodium-glucose cotransporter-2 (SGLT2) inhibitors. Studies have shown that pharmacologically-induced glucosuria with SGLT2 inhibitors raises the risk of developing genital infections and, to a relatively lesser extent, UTIs. However, a definitive dose relationship of the incidence of these infections with the SGLT2 doses is not evident in the existing data. Therefore, the precise role of glucosuria as a causative factor for these infections is yet to be fully elucidated

AB - Predisposition to genital infections and urinary tract infections (UTIs) in type 2 diabetes mellitus (T2DM) results from several factors such as glucosuria, adherence of bacteria to the uroepithelium and immune dysfunction. The tendency to develop these infections could be even higher in patients with T2DM treated with the emerging class of sodium-glucose cotransporter-2 (SGLT2) inhibitors. Studies have shown that pharmacologically-induced glucosuria with SGLT2 inhibitors raises the risk of developing genital infections and, to a relatively lesser extent, UTIs. However, a definitive dose relationship of the incidence of these infections with the SGLT2 doses is not evident in the existing data. Therefore, the precise role of glucosuria as a causative factor for these infections is yet to be fully elucidated

U2 - https://doi.org/10.1016/j.diabres.2013.12.052

DO - https://doi.org/10.1016/j.diabres.2013.12.052

M3 - Article

C2 - 24529566

SN - 0168-8227

VL - 103

SP - 373

EP - 381

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

IS - 3

ER -